Ramesh K Ramanathan
Overview
Explore the profile of Ramesh K Ramanathan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
179
Citations
10903
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhou Y, Chen X, Chen J, Kendrick C, Ramanathan R, Graham R, et al.
Sci Rep
. 2024 Apr;
14(1):9368.
PMID: 38654044
Although colorectal cancer (CRC) remains the second leading cause of cancer-related death in the United States, the overall incidence and mortality from the disease have declined in recent decades. In...
2.
Goldberg R, Sargent D, Morton R, Fuchs C, Ramanathan R, Williamson S, et al.
J Clin Oncol
. 2023 Jun;
41(19):3461-3468.
PMID: 37379691
Purpose: Three agents with differing mechanisms of action are available for treatment of advanced colorectal cancer: fluorouracil, irinotecan, and oxaliplatin. In this study, we compared the activity and toxicity of...
3.
Gordon M, Nemunaitis J, Barve M, Wainberg Z, Hamilton E, Ramanathan R, et al.
Mol Cancer Ther
. 2021 Jul;
20(10):1988-1995.
PMID: 34315767
Dilpacimab (formerly ABT-165), a novel dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and VEGF pathways. Here, we present safety, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy data from...
4.
Ando K, Ozonoff A, Lee S, Voisine M, Parker J, Nakanishi R, et al.
Clin Colorectal Cancer
. 2021 Mar;
20(2):e129-e138.
PMID: 33731288
Purpose: The camptothecin (CPT) analogs topotecan and irinotecan specifically target topoisomerase I (topoI) and are used to treat colorectal, gastric, and pancreatic cancer. Response rate for this class of drug...
5.
Ramanathan R, Von Hoff D, Eskens F, Blumenschein Jr G, Richards D, Genvresse I, et al.
Target Oncol
. 2020 Oct;
15(6):803.
PMID: 33108585
The article Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer.
6.
Goldstein D, Von Hoff D, Chiorean E, Reni M, Tabernero J, Ramanathan R, et al.
Pancreas
. 2020 Jun;
49(6):744-750.
PMID: 32541630
Objectives: This analysis investigated nomogram use to evaluate metastatic pancreatic cancer prognosis. Methods: Thirty-four baseline factors were examined in the Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT) (nab-paclitaxel plus gemcitabine vs...
7.
Ramanathan R, Von Hoff D, Eskens F, Blumenschein Jr G, Richards D, Genvresse I, et al.
Target Oncol
. 2020 Apr;
15(2):163-174.
PMID: 32314268
Background: Dual inhibition of PI3K and MAPK signaling is conceptually a promising anticancer therapy. Objective: This phase 1b trial investigated the safety, maximum tolerated dose (MTD), recommended phase II dose,...
8.
Mahalingam D, Patel M, Sachdev J, Hart L, Halama N, Ramanathan R, et al.
Br J Clin Pharmacol
. 2020 Mar;
86(9):1836-1848.
PMID: 32207164
Aim: Preclinical evidence suggests that oxidized macrophage migration inhibitory factor (oxMIF) may be involved in carcinogenesis. This phase 1 study (NCT01765790) assessed the safety, tolerability, pharmacokinetics and antitumour activity of...
9.
Strickler J, LoRusso P, Salgia R, Kang Y, Yen C, Lin C, et al.
Mol Cancer Ther
. 2020 Mar;
19(5):1210-1217.
PMID: 32127466
This first-in-human phase I study evaluated the pharmacokinetics, safety, and preliminary efficacy of telisotuzumab, formerly called ABT-700, an antagonistic antibody directed against c-Met. For dose escalation (3+3 design), 3 to...
10.
De Jesus-Acosta A, Sugar E, ODwyer P, Ramanathan R, Von Hoff D, Rasheed Z, et al.
Br J Cancer
. 2019 Dec;
122(4):498-505.
PMID: 31857726
Background: The Hedgehog (Hh) signalling pathway is overexpressed in pancreatic ductal adenocarcinoma (PDA). Preclinical studies have shown that Hh inhibitors reduce pancreatic cancer stem cells (pCSC), stroma and Hh signalling....